AspenBio Pharma Announces Closing of Public Offering; 6.1M Shares at $2

AspenBio Pharma, Inc.

, an emerging in vitro diagnostic company focused on obtaining FDA clearance for its lead product, AppyScore, which is a unique blood-based test in development designed to help physicians manage emergency room patients suspected of having acute appendicitis, today announced the closing of an underwritten public offering of 6,100,000 shares of common stock at an offering price of $2.00 per share. The number of shares and offering price reflect a one-for-six reverse stock split effected by the company on June 20, 2012. The gross proceeds to AspenBio were $12.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses.